Paper Details

  1. Home
  2. Paper Details

A comparison of budesonide with prednisolone for active Crohn's disease.

Author: DanielssonA, GoebellH, JewellD, LamersC, Lorenz-MeyerH, LöfbergR, MalchowH, OlaisonG, RutgeertsP, ThomsenO O

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Budesonide and prednisolone were both effective in inducing remission in Crohn's disease patients. Budesonide was associated with fewer glucocorticoid-associated side effects and less suppression of pituitary-adrenal function.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Patients with active Crohn's disease are often treated with corticosteroids, but the treatment has many side effects. Budesonide is a potent, well-absorbed corticosteroid, but because of a high rate of first-pass metabolism in the liver, its systemic bioavailability is low. METHODS: We ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJM199409293311304

データ提供：米国国立医学図書館（NLM）

A Comparison of Budesonide with Prednisolone for Active Crohn's Disease

Crohn's disease, a chronic inflammatory bowel disease, can significantly impact quality of life. Corticosteroids are often used to manage active Crohn's disease, but they can have significant side effects. This study compares the efficacy and safety of budesonide, a potent corticosteroid with low systemic bioavailability, with prednisolone in patients with active ileal or ileocecal Crohn's disease. The study found that both budesonide and prednisolone were effective in inducing remission, but budesonide was associated with fewer glucocorticoid-associated side effects and less suppression of pituitary-adrenal function.

Exploring Treatment Options for Crohn's Disease

This study provides valuable insights into the potential benefits of budesonide for treating active Crohn's disease. The findings suggest that budesonide may offer a more favorable risk-benefit profile compared to prednisolone, especially for patients who are concerned about the side effects of systemic corticosteroids.

Crohn's Disease and the Importance of Balanced Treatment: A Camel's Perspective

Imagine a camel traversing a desert landscape, enduring the harsh conditions and seeking nourishment. Crohn's disease, like a desert storm, can disrupt the body's delicate balance. This study explores the landscape of treatment options, offering a glimpse into the potential benefits of budesonide. Like a camel seeking a sustainable source of water, patients should carefully consider their treatment options, weighing the benefits and risks of each.

Dr.Camel's Conclusion

This study offers a valuable comparison of two treatment options for Crohn's disease, highlighting the importance of considering individual patient needs and the potential for budesonide to provide a more favorable risk-benefit profile than prednisolone. It's a reminder that the search for effective and safe treatments for chronic diseases is an ongoing journey.

Date :
  1. Date Completed 1994-10-06
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

8078530

DOI: Digital Object Identifier

10.1056/NEJM199409293311304

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.